What Is 17-hydroxyprogesterone esters

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 14, 2026

Quick Answer: 17-hydroxyprogesterone esters are synthetic derivatives of 17-hydroxyprogesterone, used primarily in medical research and hormone therapy; they were developed in the 1950s to improve metabolic stability and prolong biological activity.

Key Facts

17-hydroxyprogesterone esters were first synthesized in the 1950s by pharmaceutical researchers
Hydroxyprogesterone caproate has a half-life of approximately 10–12 days in humans
It was approved by the FDA in 1956 for the prevention of preterm birth
Clinical use declined after 2011 due to FDA safety warnings
These esters are administered intramuscularly, typically once weekly

Overview

17-hydroxyprogesterone esters are synthetic modifications of the naturally occurring steroid hormone 17-hydroxyprogesterone. These compounds were developed to enhance the hormone’s stability and extend its duration of action in the body. By attaching ester groups to the 17-hydroxyprogesterone molecule, scientists improved its solubility and resistance to metabolic breakdown.

These esters have been used primarily in reproductive medicine and endocrinology. Though not naturally occurring, they mimic the actions of progesterone and help regulate the menstrual cycle and maintain pregnancy. Their development marked a significant advancement in hormone therapy during the mid-20th century.

Hydroxyprogesterone caproate is the most well-known 17-hydroxyprogesterone ester, approved for clinical use in 1956.
These esters are prodrugs, meaning they are inactive until metabolized into active hormones in the liver.
The esterification process increases lipophilicity, allowing for slower release from intramuscular injection sites.
They bind to progesterone receptors and exhibit progestogenic activity, suppressing ovulation and supporting endometrial development.
Historically, they were used to treat luteal phase deficiency and reduce the risk of miscarriage in high-risk pregnancies.

How It Works

17-hydroxyprogesterone esters function by mimicking natural progesterone, a hormone critical for maintaining pregnancy and regulating the menstrual cycle. Once administered, the esterified form is slowly released into the bloodstream and gradually converted into active metabolites.

Mechanism of Action: The esters bind to intracellular progesterone receptors in target tissues, triggering gene expression that supports uterine quiescence and endometrial stability.
Esterification: Attaching a carboxylic acid ester to the 17-OH group increases half-life from hours to over 10 days, reducing dosing frequency.
Metabolism: Enzymes in the liver hydrolyze the ester bond, releasing free 17-hydroxyprogesterone, which is further metabolized or excreted.
Dosing Route: Administered via intramuscular injection due to poor oral bioavailability, typically at 250–500 mg weekly.
Receptor Binding: These compounds have high affinity for progesterone receptors but minimal androgenic or glucocorticoid activity, reducing side effects.
Clinical Onset: Peak serum levels occur within 24–48 hours post-injection, with sustained release over 7–10 days.

Key Comparison

Compound	Half-Life	Route	Approval Status	Primary Use
Hydroxyprogesterone caproate	10–12 days	IM injection	FDA-approved 1956, restricted after 2011	Preterm birth prevention
Medroxyprogesterone acetate	5–7 days	IM or oral	FDA-approved	Contraception, endometriosis
Norethindrone	8–12 hours	Oral	FDA-approved	Birth control
Promegestone	Not established	Oral	Marketed in Europe	Hormone replacement
17α-hydroxyprogesterone	~1 hour	Not used clinically	Not approved	Diagnostic marker

This table highlights key differences between 17-hydroxyprogesterone esters and other synthetic progestins. While hydroxyprogesterone caproate was once widely used, its application has diminished due to safety concerns and limited efficacy data.

Key Facts

Research and clinical data have revealed important insights into the pharmacology and historical use of 17-hydroxyprogesterone esters. These facts underscore both their medical significance and limitations.

1956 marked the FDA approval of hydroxyprogesterone caproate, making it one of the first synthetic progestins available for clinical use.
A 2012 NIH study found that hydroxyprogesterone caproate reduced preterm birth risk by 33% in women with prior preterm delivery.
In 2011, the FDA issued a warning about potential risks, including possible neurodevelopmental effects in offspring.
The drug was withdrawn from the U.S. market in 2020 after Pfizer discontinued production due to low demand and legal concerns.
It was classified as a Category X drug by the FDA, indicating risk outweighs benefit during pregnancy in certain cases.
Clinical trials showed a 15–20% incidence of injection site reactions, including pain and inflammation.

Why It Matters

Understanding 17-hydroxyprogesterone esters is essential for appreciating the evolution of hormone therapy and reproductive medicine. Though largely phased out, their legacy influences current treatment protocols and drug development.

They paved the way for the development of long-acting progestin therapies, including depot medroxyprogesterone acetate.
Research on their efficacy informed modern guidelines for managing preterm birth risk in high-risk pregnancies.
Regulatory actions taken in 2011–2020 highlight the importance of post-marketing surveillance in drug safety.
They demonstrated that synthetic modification of hormones could significantly extend pharmacokinetic profiles.
Their decline underscores the balance between therapeutic benefit and potential long-term adverse effects in vulnerable populations.

The study of 17-hydroxyprogesterone esters remains relevant for medical historians, endocrinologists, and pharmacologists. While no longer in widespread use, they represent a critical chapter in the advancement of hormonal treatments.